about
Tau pathology in Alzheimer disease and other tauopathiesPKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific mannersMechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SETDual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusionBlood-cerebrospinal fluid barrier permeability in Alzheimer's diseaseReduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's diseaseDown-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brainInvolvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3betaMemantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive ImpairmentI1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2ADevelopmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brainDephosphorylation of microtubule-associated protein tau by protein phosphatase 5Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1ADifferential effects of an O-GlcNAcase inhibitor on tau phosphorylationBrain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease.Dysregulation of tau phosphorylation in mouse brain during excitotoxic damageAnesthesia induces phosphorylation of tauCerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.Mechanisms of tau-induced neurodegeneration.Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegenerationCytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's diseaseElevation of the level and activity of acid ceramidase in Alzheimer's disease brain.Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell culturesEffect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells.Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.Splicing factor SC35 promotes tau expression through stabilization of its mRNA.Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease.Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1AAlzheimer's disease neurofibrillary degeneration: pivotal and multifactorialDysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic targetUp-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease.Sera from children with autism induce autistic features which can be rescued with a CNTF small peptide mimetic in ratsRegulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level.Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degenerationFailure of neuronal maturation in Alzheimer disease dentate gyrus.The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
P50
Q22252520-5A61EAC8-1E04-45B6-872D-6BB175335A1FQ24310830-26F2BCAA-3DCA-4776-8A3A-0DF5C342DA55Q24318458-BF960C90-ED6A-41D8-AFED-D07A71039E96Q24339549-543C11AE-9D5C-495F-86CA-A5A15279782AQ24631720-44533311-849D-4D55-B02A-B97C0024DDABQ24656640-A672CDC1-773F-451F-82F3-83401D9347A9Q27865198-01F2DCCF-75E2-45C2-B453-3CBC15CA8144Q28208444-9F1C33DB-B7AE-4E16-B30B-BFA493F897F1Q28551718-371D55E9-C47F-42B1-AEF9-FD773687A3E9Q28566668-0C0D92A6-DE14-4D90-B8E3-3BF24876E1C1Q28568251-D71D1E96-65FB-4B4C-AA40-B2B0EAEAFF9BQ28576295-BF477099-44C6-41EF-98EC-4E60CBC5E872Q28592850-718AB0A8-7BE0-4006-A519-AD61852CB9B6Q28730451-0D472FA0-8B27-49A0-A04C-0D9A26E05D93Q31108663-11B0D7A1-12E4-4B7C-B162-AB2591E4E5EFQ33691114-550E46A5-C9DA-4EEE-A1B9-C47ECCE4E13CQ33691128-071573EB-C5C0-45CF-8F5E-58599EF05922Q33803741-C4C91274-9AD7-486D-AA16-47390415AFE7Q33859830-3B7599EB-8C08-4610-84CD-6ECCF1916472Q33912628-91D70587-818C-4C4A-9D35-668EEBD9768DQ34155383-08BA3F15-5D15-4919-B2C1-B2A66986037AQ34283467-0F0BE433-0F87-48BC-B999-25FDCB8FFFF5Q34333004-B2D4EFE5-C155-4A87-8F0E-1EF63EAF4EA1Q34378167-F2304224-E7E3-4BDC-9FB4-375ABFAA459AQ34548310-05A8B0DD-DBCF-4BFB-8694-F9B4247614ABQ34587727-04DDBB28-0391-425F-B385-9159F75AC195Q34695519-542DF61D-252A-419B-8532-AAD64F920D2DQ34764464-DC12515F-0B93-4E67-BD22-1C0508D1FD2FQ34800508-C523205C-866A-4D52-BE99-2A33939BD291Q34814821-8A80E50C-BFF1-4674-A230-BA0D9386F5AAQ34900413-0D8D55DA-391A-473B-9D80-C8757C18AE33Q34974083-2FEAEB1E-D1B3-4833-9831-E18F4D46CC64Q35016882-530F69EF-925F-4EC3-B00A-6626CD34C9B5Q35083891-DAD15546-F253-4C10-83A7-271A8CE2857AQ35175633-744B4E92-9934-4218-87AE-7E846872B037Q35191074-E7989DB1-EDB9-4D33-90C1-7EE602DE5BBCQ35327851-90D0AEA6-B39D-4822-900A-845C4339FE86Q35327913-17EA2849-0FC9-447F-9878-76ED8CA8FB74Q35588860-A960454D-17E8-467D-83D0-24B84C2AA121Q35788903-0B7EF9FF-127B-42DF-8818-7CB786D04A2F
P50
name
Inge Grundke-Iqbal
@ast
Inge Grundke-Iqbal
@en
Inge Grundke-Iqbal
@nl
type
label
Inge Grundke-Iqbal
@ast
Inge Grundke-Iqbal
@en
Inge Grundke-Iqbal
@nl
prefLabel
Inge Grundke-Iqbal
@ast
Inge Grundke-Iqbal
@en
Inge Grundke-Iqbal
@nl
P21
P31
P569
1937-01-01T00:00:00Z
P570
2012-01-01T00:00:00Z